Intellia Therapeutics announced that its Crispr-based gene-editing treatment for hereditary angioedema, a rare swelling disorder, successfully met its main goals in a Phase 3 trial. The one-time infusion therapy reduced swelling attacks by 87% compared to placebo, with 62% of patients attack-free six months post-treatment. The treatment edits the gene in vivo to reduce overactive peptide production causing attacks, and Intellia has started FDA rolling submission aiming for a 2027 launch if approved. This marks a significant milestone as the first in vivo Crispr therapy to reach Phase 3 success, potentially offering a permanent treatment option for this condition.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
